Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs

Abstract

BackgroundPatients with chronic hepatitis B virus (HBV) infection who are hepatitis B virus e antigen (HBeAg) positive are increasingly being treated with nucleos(t)ide analogs (NUCs). However, the predictive value of serum hepatitis B virus core antibody (HBcAb) levels for HBeAg seroconversion among patients with high viral load remains unclear.MethodsThis study consisted of 74 patients with high viral load (HBV DNA >1 × 107 copies/mL) enrolled in a multicenter, randomized, controlled trial, treated with lamivudine and adefovir (N = 32) or entecavir (N = 42) for up to 96 weeks. Serum HBV DNA, quantitative hepatitis B virus surface antigen (HBsAg), HBeAg, and HBeAb was tested at each visit. Quantitative HBcAb evaluation was conducted for all the available samples in the trial, by using a newly developed double-sandwich anti-HBc immunoassay.ResultsSerum HBcAb levels were significantly higher in patients with a serum alanine aminotransferase (ALT) level more than five times the upper limit of normal (ULN) compared with patients with ALT levels within 5 × ULN (4.25 ± 0.61 vs. 3.94 ± 0.47 log10 IU/mL, P = 0.0345). Patients with HBeAg seroconversion were associated with a higher level of HBcAb at baseline, compared with those without HBeAg seroconversion (4.38 ± 0.54 vs. 4.02 ± 0.58 log10 IU/mL, P = 0.029). The area under receiver operating characteristic curve of baseline HBcAb for HBeAg seroconversion was 0.71 (95% CI: 0.55–0.86, P = 0.013). When the baseline HBcAb level was >4.375 log10 IU/mL, the sensitivity and specificity to predict HBeAg seroconversion at week 96 were 62.5% and 74.2%, and the positive likelihood ratio (LR) and negative LR were 2.42 and 0.51, respectively. The multivariate analysis result indicated that baseline serum HBcAb level was the only independent predictor for HBeAg seroconversion at week 96, with an odds ratio of 4.78.ConclusionBaseline serum HBcAb level >4.375 log10 IU/mL could satisfactorily predict HBeAg seroconversion among patients with high viral load treated with NUC.

Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma

“…But the mechanisms of carcinogenesis are different compared with NBNC-HCC [20,22]. HBV is a DNA virus that causes malignant transformation of hepatocytes mainly through gene integration into chromosomes and activation of oncogenes [25][26][27][28]. The mechanism of NBNC-HCC is still unclear, and metabolic factors may be an important factor [21,22].…”

Decreased expression levels of ELOVL6 indicate poor prognosis in hepatocellular carcinoma

“…HCC is the most common malignant tumor of the liver (26)(27)(28)(29). The result of ELOVL6 expression on the proliferation, invasion and metastasis of HCC cells was yet to be investigated, but was believed to provide insights into novel treatment options for patients with HCC.…”

Association between abdominal obesity and liver steatosis and fibrosis among patients with chronic hepatitis B measured by Fibroscan

“…Cirrhosis is characterized by diffuse fibrosis and liver tissue abnormalities, including hepatocyte necrosis and regenerative liver nodules (21). Liver cirrhosis is a indicator for end-stage liver disease, including decompensated liver disease, and HCC (22)(23)(24). Therefore, early diagnosis of liver fibrosis is important for the clinical management of CHB patients.…”